Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TRUIST FINANCIAL CORPORATION

(TFC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Truist Financial : Lorenzo Paoletti and Michael Allwin join Truist Securities

09/23/2021 | 07:12pm EDT

ATLANTA, Sept. 23, 2021 - Truist Securities today announced that Lorenzo Paoletti has joined the firm as managing director to lead the Biotech investment banking team. Working together with Michael Allwin, who joined Truist Securities in August as managing director, these experienced professionals bolster and strengthen the firm's Biotech investment banking capabilities and will focus on clients including public and private biotechs and venture firms that seed new companies with promising break-through science.

Paoletti and Allwin both previously covered the Biotech sector at Credit Suisse. They will be based in New York City.

"Over the past two years, we've been building a leading Life Sciences industry practice, and Lorenzo's and Michael's extensive experience helping Biotech companies achieve their capital formation goals and strategic objectives will benefit our clients as well as our Biotech investment banking team," said Tom Hackett, president and chief operating officer of Truist Securities.

Hackett noted other recent team additions as examples of the firm's expanded capabilities to deliver innovative solutions and creative advice to Life Sciences and Biotech clients, including investment banker Pete Cataldo, who now leads MedTech investment banking.

During that time, the firm also added healthcare sales specialist Gregg Genova and built out its extensive Life Sciences research team, including the addition of Robyn Karnauskas.

Paoletti has more than 14 years of experience in investment banking. Prior to joining Truist, Paoletti helped spearhead the Biotech investment banking effort at Credit Suisse. Before Credit Suisse, Paoletti was a managing director covering the Biotech sector on the investment banking team at RBC Capital Markets. Paoletti holds a bachelor's degree with high honors in economics from Butler University and an MBA from the New York University Stern School of Business.

Allwin was previously a senior member of the Life Sciences investment banking team at Credit Suisse focused on coverage in Biotech. Prior to Credit Suisse, he was a senior member of the equity capital markets division of RBC Capital Marlets where he helped lead origination and execution of equity and equity-linked transactions in the Biotech sector. Allwin received his bachelor's degree in political science and economics from Bucknell University.

About Truist Securities

Truist Securities is the full-service corporate and investment banking arm of Truist Financial Corporation. With a rich history extending back more than 125 years, Truist Securities offers a robust capital markets and investment banking platform that includes a comprehensive array of strategic advisory, mergers and acquisition, and capital markets capabilities for corporate and institutional clients, including sales, trading and research services in both fixed income and equity. The firm also provides corporate finance, asset finance, risk management, liquidity and treasury management solutions to meet clients' full spectrum of financial needs.

Headquartered in Atlanta, Truist Securities encompasses more than 1,400 teammates in offices located across the U.S. Learn more at www.truistsecurities.com.

© 2021 Truist Financial Corporation. Truist and Truist Securities are service marks of Truist Financial Corporation. All rights reserved. Truist Securities is the trade name for the corporate and investment banking services of Truist Financial Corporation and its subsidiaries. Securities and strategic advisory services are provided by Truist Securities, Inc., member FINRA and SIPC. Lending, financial risk management, and treasury management and payment services are offered by Truist Bank. Deposit products are offered by Truist Bank, Member FDIC.

Disclaimer

Truist Financial Corporation published this content on 23 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2021 23:11:08 UTC.


ę Publicnow 2021
All news about TRUIST FINANCIAL CORPORATION
04:05pTRUIST FINANCIAL : CFO to Present at the BancAnalysts Association of Boston Conference
PR
01:06pTRUIST FINANCIAL : Odeon Capital Adjusts Price Target for Truist Financial to $66.23 From ..
MT
10/22INSIDER SELL : Truist Financial
MT
10/20INSIDER SELL : Truist Financial
MT
10/20INSIDER BUY : Truist Financial
MT
10/20TRUIST FINANCIAL : $2M grant to UNC-Chapel Hill program will rebuild, fortify local econom..
PU
10/19TRUIST FINANCIAL : Sheffield Financial and Tohatsu America Corporation announce a retail f..
PR
10/19WALL STREET STOCK EXCHANGE : Earnings season continues to deliver
10/19ANALYST RECOMMENDATIONS : Apple, Goldman Sachs, Netflix, S&P Global, UnitedHealth...
10/18TRUIST FINANCIAL : Jefferies Adjusts Price Target for Truist Financial to $68 From $66, Ma..
MT
More news
Analyst Recommendations on TRUIST FINANCIAL CORPORATION
More recommendations
Financials (USD)
Sales 2021 22 402 M - -
Net income 2021 6 007 M - -
Net Debt 2021 - - -
P/E ratio 2021 14,4x
Yield 2021 2,88%
Capitalization 86 020 M 86 020 M -
Capi. / Sales 2021 3,84x
Capi. / Sales 2022 3,82x
Nbr of Employees 52 675
Free-Float 99,7%
Chart TRUIST FINANCIAL CORPORATION
Duration : Period :
Truist Financial Corporation Technical Analysis Chart | TFC | US89832Q1094 | MarketScreener
Technical analysis trends TRUIST FINANCIAL CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 64,44 $
Average target price 65,73 $
Spread / Average Target 1,99%
EPS Revisions
Managers and Directors
William Henry Rogers Chief Executive Officer & Director
Daryl N. Bible Chief Financial Officer & Senior Executive VP
Kelly S. King Executive Chairman
Scott E. Case Chief Information Officer
Dallas S. Clement Independent Director
Sector and Competitors